Filter Results
:
(830)
Show Results For
-
All HBS Web
(830)
- People (3)
- News (200)
- Research (576)
- Events (1)
- Multimedia (1)
- Faculty Publications (428)
Show Results For
-
All HBS Web
(830)
- People (3)
- News (200)
- Research (576)
- Events (1)
- Multimedia (1)
- Faculty Publications (428)
- April 2021
- Article
Today's Surgeon Compensation Models Fall Short: Aligning Incentives to Create More Equitable and Value-based Compensation Models
By: Susanna Gallani, Mary Witkowski, Lauren Haskins, Haley Jeffcoat, Vinita Mujumdar and Frank Opelka
Modern medicine is undergoing a transformation that involves innovative surgical approaches, increased medical treatment options, clinical care pathways that require collaboration beyond hospital walls, and health data captured by electronic health records and other...
View Details
Keywords:
Physician Compensation;
Surgeons;
Health Care and Treatment;
Business Model;
Compensation and Benefits
Gallani, Susanna, Mary Witkowski, Lauren Haskins, Haley Jeffcoat, Vinita Mujumdar, and Frank Opelka. "Today's Surgeon Compensation Models Fall Short: Aligning Incentives to Create More Equitable and Value-based Compensation Models." Bulletin of the American College of Surgeons 106, no. 4 (April 2021): 33–39.
- 2009
- Working Paper
Goals Gone Wild: The Systematic Side Effects of Over-Prescribing Goal Setting
By: Lisa D. Ordonez, Maurice E. Schweitzer, Adam D. Galinsky and Max H. Bazerman
Goal setting is one of the most replicated and influential paradigms in the management literature. Hundreds of studies conducted in numerous countries and contexts have consistently demonstrated that setting specific, challenging goals can powerfully drive behavior and...
View Details
Keywords:
Goals and Objectives;
Management Practices and Processes;
Organizational Culture;
Performance Improvement;
Behavior;
Motivation and Incentives
Ordonez, Lisa D., Maurice E. Schweitzer, Adam D. Galinsky, and Max H. Bazerman. "Goals Gone Wild: The Systematic Side Effects of Over-Prescribing Goal Setting." Harvard Business School Working Paper, No. 09-083, January 2009.
- 28 Mar 2023
- Research & Ideas
The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation
and effective in preventing severe disease, and their accelerated review will go down in history as having saved millions of lives. But COVID vaccines weren’t the first medical products to be brought to market through an expedited...
View Details
- Article
A Field Experiment on Search Costs and the Formation of Scientific Collaborations
By: Kevin Boudreau, Tom Brady, Ina Ganguli, Patrick Gaule, Eva C. Guinan, Anthony Hollenberg and Karim R. Lakhani
We present the results of a field experiment conducted at Harvard Medical School to understand the extent to which search costs affect matching among scientific collaborators. We generated exogenous variation in search costs for pairs of potential collaborators by...
View Details
Keywords:
Search Costs;
Cost;
Marketplace Matching;
Groups and Teams;
Science;
Collaborative Innovation and Invention
Boudreau, Kevin, Tom Brady, Ina Ganguli, Patrick Gaule, Eva C. Guinan, Anthony Hollenberg, and Karim R. Lakhani. "A Field Experiment on Search Costs and the Formation of Scientific Collaborations." Review of Economics and Statistics 99, no. 4 (October 2017): 565–576.
- 09 Feb 2024
- HBS Case
Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive
while Ozempic and Mounjaro have been approved to treat diabetes, but are sometimes used to lose weight. These medications are likely to profoundly alter the $76 billion weight loss industry, largely, Herzlinger says, because people have...
View Details
- March 2015
- Case
Twine Health
By: Robert S. Huckman, Ariel D. Stern and Matthew G. Preble
In late 2014, Dr. John Moore (CEO), Frank Moss (chairman), and Scott Gilroy (CTO) of Twine Health (Twine) had to resolve several challenges that threatened to restrict the widespread dissemination of its sole product, Twine. Twine was a cloud-based platform that...
View Details
Keywords:
Health Care;
Chronic Disease;
Technology Adoption;
Digital Health;
Health Acceleration Challenge;
Strategy;
Disease Management;
Health;
Health Care and Treatment;
Information Technology;
Mobile and Wireless Technology;
Health Industry;
United States;
Massachusetts
Huckman, Robert S., Ariel D. Stern, and Matthew G. Preble. "Twine Health." Harvard Business School Case 615-068, March 2015.
- February 2021 (Revised March 2022)
- Case
Marvin: A Personalized Telehealth Approach to Mental Health
By: Regina E. Herzlinger, Eshani Sharma, Andrew Nguyen, Thomas Arsenault, Carin-Isabel Knoop and Julia Kelley
More than one third of Americans were said to suffer some type of behavioral health ailment at some point in their lifetime, with many people requiring chronic therapy or intervention. Despite significant clinical needs, access to reliable treatment has been difficult...
View Details
Keywords:
Mental Health;
Applications;
Startup Management;
Telehealth;
Health Care Entrepreneurship;
Health & Wellness;
Health Care;
Health Care and Treatment;
Customization and Personalization;
Internet and the Web;
Entrepreneurship;
Growth and Development Strategy;
Applications and Software
Herzlinger, Regina E., Eshani Sharma, Andrew Nguyen, Thomas Arsenault, Carin-Isabel Knoop, and Julia Kelley. "Marvin: A Personalized Telehealth Approach to Mental Health." Harvard Business School Case 321-127, February 2021. (Revised March 2022.)
- March 2018
- Teaching Note
Twine Health
By: Robert S. Huckman and Ariel D. Stern
In late 2014, Dr. John Moore (CEO), Frank Moss (chairman), and Scott Gilroy (CTO) of Twine Health (Twine) had to resolve several challenges that threatened to restrict the widespread dissemination of its sole product, Twine. Twine was a cloud-based platform that...
View Details
- Article
Affording to Wait: Medicare Initiation and the Use of Health Care
By: Guy David, Philip Saynisch, Victoria Acevado-Perez and Mark D. Neuman
Delays in receipt of necessary diagnostic and therapeutic medical procedures related to the timing of Medicare initiation at age 65 years have potentially broad welfare implications. We use 2005–2007 data from Florida and North Carolina to estimate the effect of...
View Details
Keywords:
Medicare;
Behavior;
Insurance;
Health Care and Treatment;
Insurance Industry;
Public Administration Industry;
Health Industry;
North Carolina;
Florida
David, Guy, Philip Saynisch, Victoria Acevado-Perez, and Mark D. Neuman. "Affording to Wait: Medicare Initiation and the Use of Health Care." Health Economics 21, no. 8 (August 2012): 1030–1036.
- 22 Aug 2022
- Research & Ideas
Can Amazon Remake Health Care?
At a time when health care providers have gone all in on telemedicine, Amazon, the world’s biggest online retailer, surprised Wall Street in late July when it announced it would acquire 1Life Healthcare Inc., which runs the subscription-based One View Details
- January 2022
- Case
Somatus: Value-Based Kidney Care (A)
By: Ariel D. Stern, Robert S. Huckman and Sarah Mehta
When Dr. Ikenna Okezie founded Somatus, a value-based kidney care provider, his goal had been nothing short of transforming kidney care delivery in the United States. Rather than relying on dialysis, a costly and intensive treatment for late-stage kidney disease, the...
View Details
Keywords:
Business Startups;
Disruption;
Entrepreneurship;
Health;
Health Care and Treatment;
Health Disorders;
Medical Specialties;
Innovation and Invention;
Disruptive Innovation;
Management;
Strategy;
Business Strategy;
Value;
Value Creation;
Health Industry;
United States;
Virginia
Stern, Ariel D., Robert S. Huckman, and Sarah Mehta. "Somatus: Value-Based Kidney Care (A)." Harvard Business School Case 622-009, January 2022.
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing...
View Details
Keywords:
AI;
Genetic Engineering;
Medicine;
Health Care and Treatment;
Genetics;
Innovation Strategy;
Business and Stakeholder Relations;
Medical Specialties;
Innovation and Invention;
Entrepreneurship;
Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- 06 Sep 2019
- Blog Post
The Business of Medicine: MD/MBA Students Having an Impact
These Harvard Medical School (HMS) students are already making a difference in the health care community. Now, they are at HBS fine-tuning their leadership skills in preparation of receiving their MD/MBA. Each year, MD/MBA applicants...
View Details
- Article
Beyond Magic Bullets: True Innovation in Health Care
By: Vaibhav A. Narayan, Marco Mohwinckel, Gary Pisano, Michael Yang and Husseini Manji
The molecular medicine revolution—based on advances in fields such as genomics and network modeling in the decade since the human genome sequence was completed—has changed the way we think about, study, and approach the development of novel therapies. However, these...
View Details
Keywords:
Integration;
Business Model;
Organizational Structure;
Health Care and Treatment;
Innovation and Invention;
Pharmaceutical Industry
Narayan, Vaibhav A., Marco Mohwinckel, Gary Pisano, Michael Yang, and Husseini Manji. "Beyond Magic Bullets: True Innovation in Health Care." Nature Reviews: Drug Discovery 12, no. 2 (February 2013): 85–86.
- 2023
- Working Paper
The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina
By: Sebastian Calónico, Rafael Di Tella and Juan Cruz Lopez Del Valle
We document the diffusion of nebulized ibuprofen in Argentina as a treatment for COVID-19. As the pandemic spread, this clinically unsupported drug reached thousands of patients, even some seriously ill, despite warnings by the regulator and medical societies. Detailed...
View Details
Keywords:
COVID-19;
Health Care and Treatment;
Health Pandemics;
Adoption;
Behavior;
Governing Rules, Regulations, and Reforms;
Learning
Calónico, Sebastian, Rafael Di Tella, and Juan Cruz Lopez Del Valle. "The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina." NBER Working Paper Series, No. 31781, October 2023.
- October 2009
- Case
Medisys Corp.: The IntensCare Product Development Team
By: Anne Donnellon and Joshua D. Margolis
Key topics include designing teams, managing teams, managing conflict, group dynamics, project management, product development, interdepartmental relations, and organizational change. MediSys, a U.S.-based medical equipment maker, has been developing IntensCare, a new...
View Details
Keywords:
Project Management;
Interdepartmental Relations;
Organizational Change;
Leadership;
Conflict Management;
Interpersonal Communication;
Groups and Teams;
Product Design;
Product Development;
Organizational Change and Adaptation;
Health Care and Treatment;
Power and Influence;
Medical Devices and Supplies Industry;
United States
Donnellon, Anne, and Joshua D. Margolis. "Medisys Corp.: The IntensCare Product Development Team." Harvard Business School Brief Case 094-059, October 2009.
- October 2013
- Article
The Strategy That Will Fix Health Care
By: Michael E. Porter and Thomas H. Lee
In health care, the days of business as usual are over. Around the world, every health care system is struggling with rising costs and uneven quality, despite the hard work of well-intentioned, well-trained clinicians. Health care leaders and policy makers have tried...
View Details
Keywords:
Organizational Change and Adaptation;
Strategy;
Value;
Customer Focus and Relationships;
Health Care and Treatment;
Health Industry
Porter, Michael E., and Thomas H. Lee. "The Strategy That Will Fix Health Care." Harvard Business Review 91, no. 10 (October 2013): 50–70.
- 17 Jul 2016
- Working Paper Summaries
Tort Reform and Innovation
- 12 Dec 2022
- Research & Ideas
Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them
Black patients and their doctors may be more open to new medications if drug trials included more Black people, new research shows. Currently, Black Americans represent just 5 percent of drug trial participants. Nearly three-quarters of...
View Details